// App-Quantinova.ai

: Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).

Researchers

Presenter

  • Tamim Niazi

Principal Investigators

  • Abdenour Nabid

  • Redouane Bettahar

  • Linda S. Vincent

  • Andre-Guy Martin

  • Marjory Jolicoeur

  • Michael Yassa

  • Maroie Barkati

  • Levon Igidbashian

  • Boris Bahoric

  • Robert Archambault

  • Hugo Villeneuve

  • James M Tsui

  • MD Mohiuddin

Medical Centers

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada

  • Centre Hospitalier Regional de Rimouski - Centre de Cancer, Rimouski, QC, Canada

  • Pavillon Ste-Marie CHRTR, Trois Rivieres, QC, Canada

  • Hotel-Dieu De Quebec Laval Univ, Quebec, QC, Canada

  • Hopital Notre-Dame, CHUM, Montreal, QC, Canada

  • Hopital Maisonneuve-Rosemont, Montreal, QC, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Cite De La Sante De Laval, Laval, QC, Canada

  • Hopital de Gatineau, Gatineau, QC, Canada

  • Council of State Science Supervisors de Chicoutimi, Chicoutimi, QC, Canada

  • Montreal University, Montreal, QC, Canada

  • Saint John Regional Hospital, Saint John, NB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT01444820

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved